ABT: Abbott Laboratories Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ABT: Abbott Laboratories

ABT 125.16

-1.1%

9:48 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: HerbVic	8/11/2004 12:02:28 PM
	of 33

FDA Approves Abbott Laboratories' HUMIRA(R) (adalimumab) to Improve Physical Function in Rheumatoid Arthritis (RA) Patients ABBOTT PARK, Ill., Aug. 10 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) has approved an expanded indication for Abbott Laboratories' rheumatoid arthritis (RA) treatment, HUMIRA(R) (adalimumab), to include improvement in physical function for adult patients with moderately to severely active RA. Improvement in physical function is an important goal of therapy for RA patients, who often experience disability and loss of function that can greatly reduce quality of life. Many people with RA are unable to groom or dress themselves and some cannot walk due to the crippling effects of their disease. The FDA based its approval on a supplemental Biologics Licensing Application (sBLA) filed by Abbott on Sept. 30, 2003. In 2002, HUMIRA was approved to reduce signs and symptoms and inhibit the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease modifying antirheumatic drugs (DMARDs). <snip> prnewswire.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next